The effect of sex on immune responses to a homocitrullinated peptide in the DR4-transgenic mouse model of Rheumatoid Arthritis by Cairns, Ewa et al.
Western University 
Scholarship@Western 
Bone and Joint Institute 
1-1-2020 
The effect of sex on immune responses to a homocitrullinated 












See next page for additional authors 
Follow this and additional works at: https://ir.lib.uwo.ca/boneandjointpub 
 Part of the Medicine and Health Sciences Commons 
Citation of this paper: 
Cairns, Ewa; Saunders, Sheri; Bell, David A.; Blackler, Garth; Lac, Patrick; and Barra, Lillian, "The effect of 
sex on immune responses to a homocitrullinated peptide in the DR4-transgenic mouse model of 
Rheumatoid Arthritis" (2020). Bone and Joint Institute. 194. 
https://ir.lib.uwo.ca/boneandjointpub/194 
Authors 
Ewa Cairns, Sheri Saunders, David A. Bell, Garth Blackler, Patrick Lac, and Lillian Barra 
This article is available at Scholarship@Western: https://ir.lib.uwo.ca/boneandjointpub/194 
The effect of sex on immune responses to a homocitrullinated peptide in the
DR4-transgenic mouse model of Rheumatoid Arthritis
Ewa Cairns a,b, Sheri Saunders a, David A. Bell a, Garth Blackler a, Patrick Lac a,c, Lillian Barra a,b,*
a Department of Microbiology and Immunology, The University of Western Ontario, London, ON, Canada
b Department of Medicine/Rheumatology, The University of Western Ontario, London, ON, Canada
c Current Address: Michael Smith Genome Sciences Centre, BC Cancer Research Centre, Department of Pathology and Laboratory Medicine, University of British Columbia,
Vancouver, BC, Canada










A B S T R A C T
Rheumatoid Arthritis (RA) is more common and severe in women compared to men. Both women and men with
RA express autoantibodies to post-translationally modified antigens, including citrullinated and homocitrullinated
proteins or peptides. These autoantibodies are strongly linked with the HLA-DR4 gene. The objective of this study
was to determine sex differences in immune responses to homocitrullinated antigens. We used a humanized
animal model of RA, DR4-transgenic mice and immunized them with a homocitrullinated peptide called
HomoCitJED. Immune responses in these mice were measured for splenocyte proliferation by tritiated thymidine
incorporation, serum autoantibody production by ELISA and cytokine levels by multiplex. We found that T cell
and antibody responses to homocitrullinated antigens were similar in male and female mice. However, we found
sex differences in serum cytokine profiles with female mice having higher ratio of IL-1α to IL-5, suggesting im-
balances in immune regulation. This is the first study to report that immune responses to homocitrullinated
antigens can be differentiated by sex.
1. Introduction
Rheumatoid Arthritis (RA) is a systemic inflammatory autoimmune
disease predominantly affecting the synovial joints. It is 2–3 times more
common in women who are less likely to respond to therapies and ach-
ieve remission than men [1–5]. The reasons for sex and/or gender dif-
ferences in RA are incompletely understood: in addition to
sociodemographic factors, sex differences in immune responses are likely
to contribute. The X-chromosome contains many immune-related genes
and sex hormones are known to affect immune cell function [6]. In RA,
the disease improves with pregnancy and testosterone-deficient men are
more likely to develop RA [7,8]. In some studies, T cell subtypes and
autoantibody expression were shown to differ amongst men and women
with RA [9–11].
RA is characterized by the production of autoantibodies: rheumatoid
factor (RF) and anti-citrullinated protein/peptide antibodies (ACPA)
were the first to be described [12,13]. More recently,
anti-homocitrullinated protein/peptide antibodies (AHCPA), also known
as anti-carbamylated protein antibodies (anti-CarP), were shown to be
specifically expressed in a large proportion of patients with RA, including
those negative for ACPA [14–16]. Like ACPA, AHCPA is associated with
more severe erosive disease [16,17]. There is conflicting evidence
whether women with RA are more likely to be positive for ACPA [10,11].
ACPA is highly associated with the strongest genetic risk factor for
RA, HLA-DR4 alleles encoding major histocompatibility complex (MHC)
II containing a consensus sequence known as the Shared Epitope [18].
The Shared Epitope binds to citrullinated peptides with high affinity
leading to T cell activation and the production of ACPA [19,20].
Homocitrulline and citrulline are structurally similar and in silico, a
homocitrullinated collagen II peptide was found to bind the Shared
Epitope [14].Mice transgenic for the Shared Epitope (DR4tg) immunized
with a homocitrullinated peptide (HomoCitJED) developed T and B cell
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responses to homoctirullinated antigens, but not to peptides containing
lysine instead of homocitrulline on the same amino acid backbone [21].
HomoCitJED is a synthetic peptide that captures immune reactivities to
multiple naturally-occurring homocitrullinated and citrullinated pro-
tein/peptides known to be present in the joints of RA patients [14,15].
The objective of the present study was to determine sex differences in
immune responses to homocitrullinated antigens.
2. Materials and methods
2.1. Antigens
The following antigens were employed in this study: a) Homoci-
trullinated JED (HomoCitJED), which is an 18 amino acid long cyclic
peptide with 9 homocitrullines [14,15], synthesized by Creative Peptides
(Shirley, NY, USA); b) human fibrinogen (Fib) from VWR and c) homo-
citrullinated human fibrinogen (HomoCitFib). Homocitrullination was
performed as previously described [14,22].
2.2. Mice and immunizations
DR4-IE transgenic mice on C57Bl/6 background (referred to as
DR4tg) lacking endogenous MHC class II molecules were bred in-house
[22]. They were compared to wild type C57Bl/6 (B6) (The Jackson
Laboratories, Maine, USA). Mice were housed at the Animal Care and
Veterinary Services pathogen-free facility at the University of Western
Ontario according to the guidelines of the Canadian Council on Animal
Care. The study was approved by the Animal Care and Use Committee
(The University of Western Ontario, London, ON, Canada). Female and
male mice received primary and booster immunization of HomoJED
peptide (100 μg each time) or PBS control via subcutaneous (sc) route as
described by Lac et al. [21].
2.3. Splenocyte proliferation
At various times post-immunizations, mouse spleens were harvested
and splenocytes were cultured in media containing 100 μg/mL of
HomoCitJED or 1 μg/mL Concanavalin A (ConA) (Sigma) or media alone.
After 54 h of culture, half of the supernatant was replaced by media
containing 3H-thymidine (1 μCi/well). After an additional 18 h, radio-
activity was measured. Proliferation is reported as a Stimulation Index
(SI; cpm of samples with HomoCitJED or ConA/cpm of samples with
media) þ/ standard deviation. SI > 2 was considered as a positive
proliferative response. Samples were tested at least in quadruplicate
(coefficient of variation <20%). Additional methodological details can
be found in Lac et al. [21].
2.4. Antibody assays
Each mouse serum sample was tested at least in duplicate for the
presence of IgG antibodies to HomoCitJED, unmodified and homoci-
trullinated human fibrinogens using ELISA [21]. Antibody concentra-
tions to each antigen are expressed as relative units (RU)/mL which were
determined from a standard curve generated from a pooled reference
mouse serum. The cut-off for positive values was the lower detection
limit of the ELISA (0.1 OD, equivalent to 20.3 RU/mL and 2.9 RU/mL for
anti-HomoCitJED and anti-HomoCitFib antibody, respectively). For each
mouse sample, the coefficient of variation across replicates was <20%.
2.5. Cytokines and chemokines assay
Twenty-four cytokines and chemokines were measured in the sera of
HomoCitJED immunized DR4tg and B6 mice on days 10 and 70 post-
immunization using a commercial multiplex immunoassay (Thermo-
Fisher). Samples were tested in duplicate.
2.6. Statistical analyses
Comparisons were performed for four groups of mice: female DR4tg,
male DR4tg, female B6 and male B6. T cell proliferation and antibody
responses at each timepoint were compared using 2-way ANOVA with
Bonferroni correction (p < 0.001 considered statistically significant).
Frequency of positive proliferative and detectable antibody responses
over the course of the study were compared using Chi-square test (p <
0.01). Discriminant analysis of the log-transformed cytokine data was
performed to determine whether the cytokine profiles for the four mouse
groups were distinguishable (p < 0.05). Stepwise discriminant analysis
was also performed to identify the cytokines that contribute most to the
group separation. Individual log-transformed cytokine levels were
compared using the Mann-Whitney test and corrected for multiple
comparisons (p < 0.01). Cytokine and chemokine levels at day 10 and
day 70 were similar and these were therefore combined. Statistical an-
alyses were performed using GraphPad Prism 6.0 and SAS 9.4 software.
3. Results
3.1. Splenocyte proliferative responses
Splenocytes from HomoCitJED immunized DR4tg and B6 mice were
isolated at various time points and examined for T cell proliferative re-
sponses to HomoCitJED and ConA (Fig. 1, Supplementary Fig. 1). Over
the time course of the study, there were no significant differences in T cell
responses to HomoCitJED or ConA in female versus male DR4tg and B6
mice. Responses to HomoCitJED were more frequent in DR4tg compared
to B6 mice: 24/116 (21%) versus 8/98 (8%); p¼ 0.0150. For DR4tg mice
the responses were stable over time; whereas, for B6 mice, the responses
were higher at later timepoints (p < 0.0001). There were no significant
differences in responses to ConA between mouse strains and over time.
PBS immunized mice did not have detectable splenocyte proliferative
responses to HomoCitJED but responded to ConA as expected with no
significant differences by strain or sex (data available from corresponding
author).
3.2. Antibody responses to homocitrullinated antigens
After immunization with HomoCitJED, serum IgG antibodies to this
peptide and to HomoCitFib were mostly detected from day 30 to day 100
in DR4tg and B6 mice (Fig. 2 and Tables 1 and 2). For DR4tg mice, the
levels peaked at day 70 and for B6, day 50; changes over time were
significantly different for DR4tg (p < 0.0001), but not B6 mice. There
were no significant differences in the levels or frequency of antibodies in
female versus male mice for both strains over the course of the study. The
number of mice positive for anti-HomoCitJED antibodies was higher in
DR4tg versus B6 mice: 90/161 (56%) and 39/137 (28%), respectively; p
< 0.0001. High positive AHCPA (>than the 75th percentile) was un-
common in B6 mice: 8/137 (6%) vs. 39/161 (24%) in DR4tg mice for
anti-HomoCitJED antibodies (p < 0.0001) and 13/144 (9%) vs. 35/157
(22%) in DR4tg for anti-HomoCitFib antibodies (p ¼ 0.0017). DR4tg
males had higher mean antibody levels (p < 0.0001) than B6 males;
results were similar for females but did not reach statistical significance.
PBS immunizedmice did not have any detectable AHCPA and none of the
mice had antibody responses to unmodified human fibrinogen (data
available from corresponding author).
3.3. Cytokine and chemokine responses
Twenty of twenty-four cytokines/chemokines were detected in the
sera of HomoCitJED immunized DR4tg and B6 mice. The following were
not detected in any of the animals: IL-4, IL-9, IL-13 and TGFβ2. Four mice
had detectable IL-1β, three had IL-2, two had IL-25 and nine had IL-17;
however, the mean values for these cytokines were below the detection
limit and they were excluded from further analyses. The included
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cytokines/chemokines (N ¼ 16) are shown in Table 3. In DR4tg mice, IL-
5 was significantly higher in females compared to males (p ¼ 0.0004).
Both male and female B6 mice had higher levels of IL-12p40/IL-23 than
DR4tg mice (p < 0.0001). Analyses of the levels for the other individual
cytokines and chemokines did not reveal any other statistically signifi-
cant differences.
Discriminant analysis was performed to determine whether a profile
consisting of all the detectable cytokines and chemokines (N ¼ 16) could
differentiate mice by sex and strain. This analysis generated 3 functions
(Can1, Can2, Can3), accounting for 86% of the variance seen in the
dataset. Can1 primarily differentiated the cytokine profile of DR4tg vs.
B6 mice (p < 0.0001) and Can2, female vs. male DR4tg mice (p ¼
0.0118) (Fig. 3). Group differentiation by Can3 was not significant (p ¼
0.4311) (data available from corresponding author). The accuracy of the
group differentiation by the discriminant analysis model was 92%. The
cytokines that contributed most to the differentiation between mouse
groups were: IL-12p40/IL-23 (R2 ¼ 0.7346, p < 0.0001), IL-1α (R2 ¼
0.3891, p ¼ 0.0009) and IL-5 (R2 ¼ 0.2193, p ¼ 0.0404).
4. Discussion
In this study we found that there were no sex differences in T cell
Fig. 1. Splenocyte proliferative responses in DR4tg (●Females; Males) and B6 (▴Females; Males) mice. Splenocytes isolated from HomoCitJED-immunized DR4tg
(A) and B6 (B) mice were cultured in the presence of 100 μg/mL of HomoCitJED. Splenocyte proliferation is shown as a mean stimulation index (SD). Positive
proliferative responses were defined as stimulation indices 2.0. Each symbol represents one mouse; N ¼ 8–16.
Fig. 2. Sera antibody responses in DR4tg (●Females; Males) and B6 (▴Females; Males) mice. Sera at various time points were tested for IgG anti-HomoCitJED
antibodies in DR4tg (A) and B6 (B) mice and for IgG anti-HomoCitFib antibodies in DR4tg (C) and B6 (D) mice. Values are in RU/mL (SD). Each symbol repre-
sents one mouse; N ¼ 8–29.
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proliferative responses and antibody responses to homocitrullinated an-
tigens in DR4tg mice immunized with a homocitrullinated peptide.
However, using discriminant analysis, the cytokine profile of female mice
was significantly different from male mice. To our knowledge, this is the
Table 1
Sera IgG anti-homocitrullinated JED antibody responses.
DR4tg Mice Females Males
Days 10 30 50 70 100 10 30 50 70 100























Positive, N (%) 4 (25) 15 (100) 9 (75) 6 (75) 10 (56) 3 (10) 13 (76) 11 (73) 8 (100) 11 (48)
High Positive, N
(%)
0 (0) 8 (53) 2 (17) 4 (50) 2 (11) 1 (4) 3 (18) 5 (33) 6 (75) 8 (35)
B6 Mice Females Males
Days 10 30 50 70 100 10 30 50 70 100
N 27 15 15 15 9 25 20 19 17 14
Mean (SD), RU/
mL







Positive, N (%) 0 (0) 3 (25) 4 (33) 5 (39) 3 (33) 0 (0) 4 (25) 7 (54) 8 (57) 5 (42)
High Positive, N
(%)
0 (0) 0 (0) 3 (25) 0 (0) 0 (0) 0 (0) 1 (6) 4 (31) 0 (0) 0 (0)
Days are post-HomCitJED primary immunization.
RU/mL ¼ relative units per millilitre.
Positive values were defined as higher than the detection limit of the assay (>20.3 RU/mL).
High positive values were defined as > than the 75th percentile ¼ 340 RU/mL.
Table 2
Sera IgG anti-homocitrullinated fibrinogen antibody responses.
DR4tg Mice Females Males
Days 10 30 50 70 100 10 30 50 70 100
N 15 18 14 9 18 20 16 16 9 22
Mean (SD), RU/mL 0.8 (3.3) 16.3 (20.5) 58.8 (104.1) 226.5 (296.8) 23.4 (40.8) 0.1 (0.2) 29.4 (42.4) 71.5 (109.7) 131.6 (188.3) 48.3 (73.9)
Positive, N (%) 1 (7) 11 (61) 5 (36) 5 (56) 6 (33) 0 (0) 8 (50) 7 (44) 8 (89) 9 (41)
High Positive, N (%) 0 (0) 2 (11) 2 (14) 3 (33) 5 (28) 0 (0) 4 (25) 7 (44) 4 (44) 8 (36)
B6 Mice Females Males
Days 10 30 50 70 100 10 30 50 70 100
N 21 13 11 11 11 14 16 16 16 15
Mean (SD), RU/mL 1.4 (4.7) 14.0 (18.9) 81.6 (274.3) 9.6 (14.7) 17.3 (37.6) 0.8 (3.7) 2.9 (7.5) 24.4 (42.6) 10.4 (27.2) 7.1 (16.3)
Positive, N (%) 2 (10) 6 (46) 5 (45) 8 (72) 4 (36) 1 (7) 3 (19) 8 (50) 5 (31) 6 (40)
High Positive, N (%) 0 (0) 1 (8) 2 (18) 2 (18) 2 (18) 0 (0) 0 (0) 3 (19) 2 (13) 1 (7)
Days are post-HomCitJED primary immunization.
RU/mL ¼ relative units per millilitre.
Positive values were defined as higher than the detection limit of the assay (>2.9 RU/mL).
High positive values were defined as > than the 75th percentile ¼ 40 RU/mL.
Table 3
Serum Log-Transformed Cytokine and Chemokine levels.
Cytokine




Female Male p-value Female Male p-value p-value p-value
TGFβ1b 10.968 (0.702) 11.246 (0.591) 0.3507 10.969 (0.812) 11.528 (0.444) 0.0722 0.9972 0.2429
TGFβ2b 7.552 (0.473) 7.520 (0.503) 0.8876 7.501 (0.703) 7.833 (0.559) 0.2703 0.8532 0.2054
IFNγ 1.845 (0.903) 1.675 (0.739) 0.6501 2.375 (1.686) 1.813 (1.011) 0.3776 0.3923 0.7318
IL-1α 1.309 (0.826) 0.665 (0.731) 0.0814 1.277 (1.158) 0.431 (0.337) 0.0398 0.9437 0.3704
IL-5 3.134 (0.245) 2.402 (0.475) 0.0004 2.773 (0.554) 2.776 (0.688) 0.9912 0.0756 0.1738
IL-6 1.431 (1.948) 1.688 (2.140) 0.7825 1.660 (2.253) 1.835 (1.625) 0.8441 0.8109 0.8640
IL-10 0.855 (0.471) 0.291 (0.635) 0.0369 1.269 (0.853) 0.783 (1.048) 0.2703 0.1951 0.2202
IL-12p40/IL-23 2.550 (0.511) 2.117 (0.514) 0.0751 3.899 (0.653) 3.723 (0.403) 0.4784 <.0001 <.0001
IL-18 6.214 (0.385) 6.036 (0.462) 0.3619 5.748 (1.049) 5.171 (1.454) 0.3227 0.2036 0.0900
MCP-1 2.773 (1.532) 2.343 (1.359) 0.5151 2.185 (2.017) 2.938 (0.520) 0.2697 0.4744 0.2123
MIP-1α 0.514 (0.395) 0.447 (0.171) 0.6315 0.600 (0.203) 0.594 (0.386) 0.9628 0.5448 0.2863
MIP-1β 0.909 (0.491) 0.694 (0.427) 0.3096 0.943 (0.555) 0.893 (0.409) 0.8225 0.8856 0.2998
MIP-2 1.887 (0.478) 1.910 (0.503) 0.9193 1.674 (0.493) 2.161 (0.224) 0.0107 0.3393 0.1737
Eotaxin 3.454 (2.775) 3.981 (2.142) 0.6405 3.067 (2.850) 5.080 (1.348) 0.0586 0.7618 0.1864
RANTES 2.125 (1.378) 2.479 (1.468) 0.5847 3.178 (2.525) 4.2835 (1.252) 0.2306 0.2622 0.0084
VEGF 1.538 (0.956) 0.896 (0.958) 0.1510 1.674 (1.180) 1.898 (0.918) 0.6430 0.7804 0.0283
Values are mean levels in pg/mL (SD), unless otherwise indicated.
E. Cairns et al. Journal of Translational Autoimmunity 3 (2020) 100053
4
first published study to investigate sex differences in anti-
homocitrullinated immune responses in mouse models of RA.
The DR4tg mouse model used in this study closely resembles human
RA in that it expresses human Shared Epitope [20]. We and others have
previously shown that DR4tg mice have immune responses to antigens
known to be involved in the pathogenesis of RA and can develop RA-like
inflammatory arthritis [22–24]. In humans, RA is more common in fe-
males [3]; in DR4tg mice, arthritis was also more common in females
when immunized with collagen II [24]. The mechanistic role of immune
responses in the observed sex differences in RA are unclear. Although
evidence supports arthritogenicity of ACPA bib25[19,25] and some
studies show that ACPA are more common in women with RA [10,11],
most studies either did not report or did not find sex differences in the
expression of the autoantibodies. Similarly, we found that the frequency
and levels of AHCPA (anti-HomoCitJED antibodies) were not signifi-
cantly different in women compared to men in a cohort of patients with
established RA that we previously published [15]: 70.1 (SD 138.0)
RU/mL, (47/100) positive and 85.9 (135.7) RU/mL (22/37 positive),
respectively. Therefore, our findings of no sex differences in antibody
expression in the DR4tg mouse model are consistent with prior human
studies.
There are a paucity of studies investigating sex differences in T cell
function and frequency of T cell subtypes in RA and the results are
conflicting: Aldridge et al. did not find significant sex differences in the
number or proportion of peripheral T cell subsets [9]; whereas, Mateen
et al. found that men had a higher proportion of Th17 cells than women
[26]. Both studies investigated patients with early, untreated RA and the
reason for the discrepancy of their results is unknown but could be due to
other differences in the populations, such as age, genetics and environ-
mental exposures. In these studies, which had small sample sizes, it can
be difficult to account for possible confounders; therefore, animal models
with controlled settings can provide insight into the sex differences. In
our study of HomoCitJED immunized DR4tg mice, specific T cell prolif-
erative responses to homocitrullinated antigens and responses to a gen-
eral T cell mitogen (ConA) did not reveal any sex differences. Behrens
et al. found that sex effects in T cell proliferative responses to collagen II
peptides in collagen II-immunized DR4tgmice depended upon the type of
antigen presenting cell; females had higher responses to peptides pre-
sented by B cells and males by dendritic cells [27]. In our experiments,
we studied splenocytes and did not examine separately the T cell re-
sponses to HomoCitJED presented by different antigen presenting cells.
Another limitation of our study is that we did not analyze multiple
immune cell types, including T cell subtypes. However, we measured
various serum cytokines and chemokines, which can be markers of im-
mune cell phenotype. We found that the cytokine/chemokine profile
differentiated HomoCitJED immunized female from male mice by
discriminant analysis. The differences in the profile were mostly driven
by IL-1α and IL-5 levels, which were higher in female mice. IL-1α is a pro-
inflammatory cytokine involved in the pathogenesis of RA; it activates
immune cells in the joint to release proteoglycans and proteases, leading
to cartilage destruction and bone erosions [28]. Studies have shown that
women with RA are more likely to have joint erosions [5] and that an
antagonist of the IL-1 receptor effectively treats RA [29]. Less is known
about the role of IL-5 in RA. It primarily acts upon eosinophils and ap-
pears to be involved in the regulatory mechanisms leading to the reso-
lution of inflammation in autoimmunity [30]. In a serum transfer mouse
model of RA, over-expression of IL-5 resulted in decreased arthritis
severity [31]. In our DR4tg model, females had a higher ratio of
IL-1α/1L-5 compared to males (0.42 and 0.28, respectively), suggesting
that in females the regulation of pro-inflammatory immune responses
could be dysfunctional and lead to a higher incidence and severity of
arthritis. Our HomoCitJED immunized DR4tg mice of either sex did not
develop arthritis, likely due to the absence of the homocitrullinated or
citrullinated targets in the joint.
Themain focus of our study was DR4tgmice as amodel for RA, but we
also investigated wild-type B6 mice. We found that the effect of sex on
immune responses to HomoCitJED were similar for B6 and DR4tg mice.
Consistent with our prior study where the Shared Epitope influenced
immune responses to homocitrullinated peptides, B6 mice were less
likely to develop T cell and antibody responses to homocitrullinated
antigens [21]. Surprisingly, B6 mice had higher levels of IL-12p40/IL-23
than DR4tg mice. These cytokines activate Th1 and Th17 cells, respec-
tively that are critical in RA disease mechanisms [32]. However, IL-12
has been shown to be a regulator of autoantibody production [33,34]
and may contribute to the lower AHCPA levels we detected in B6 versus
DR4tg mice.
In conclusion, HomoCitJED induces higher levels of IL-1α and IL-5 in
female compared to male DR4tg mice, which may provide insight into
mechanisms of sex differences in RA. Although T cell proliferative re-
sponses to HomoCitJED and levels of IgG AHCPA did not vary by sex, we
did not investigate specific T cell subtypes nor different IgG isotypes.
Given the sex differences we found in the cytokine profile, HomoCitJED
immunized female mice may have an imbalance towards a more pro-
inflammatory state. Future studies in mouse models and humans are
required to further understand the mechanisms of sex differences in RA
pathogenesis to identify sex-specific biomarkers and treatments.
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